Flawed GVK studies: EMA sticks with suspension as Indian CRO fights on
This article was originally published in SRA
There is no respite for GVK Biosciences, the Indian contract research organization in the eye of a storm over allegations of data manipulation by European regulators. The European Medicines Agency said today it was sticking with its previous recommendation to suspend a large number of drugs whose approvals in the EU were primarily based on clinical studies conducted at GVK's Hyderabad unit1,2. GVK for its part said it would continue to fight its case.
You may also be interested in...
The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.
Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.